Click Here to return To Results

 

Tocilizumab Treatment for New Onset Refractory Status Epilepticus Ann Neurol 84:940-945, Jun, J.,et al, 2018 See this aricle in Pubmed Article Abstract We investigated the therapeutic potential of the interleukin-6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n=5) or without rituximab (n=2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction complications efficacy interleukin 6 new onset refractory status epilepticus safety seizure,intractable seizure,treatment of status epilepticus status epilepticus,intractable tocilizumab treatment of neurologic disorder

Click Here to return To Results